Biogenerics After All? US FDA Wants Biosimilar Process To Mirror Generics

 
• By Ramsey Baghdadi
  
US FDA seems poised to move away from the ‘quite burdensome’ testing framework it currently uses for biosimilars. (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Biosimilars & Generics